Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F

Slides:



Advertisements
Similar presentations
NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,
Advertisements

Assessment of Differentiation and Progression of Hepatic Tumors Using Array-Based Comparative Genomic Hybridization  Doris Steinemann, Britta Skawran,
Inflammatory Myofibroblastic Tumor of the Left Main Stem Bronchus
Genomic analysis: Toward a new approach in breast cancer management
Figure 1. Validation of the chromosome 22 array
The array comparative genomic hybridization (aCGH/CMA) technology
An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.
High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis  Robert A.A. van Boerdonk, MSc, Johannes.
Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia  Shelly R. Gunn,
Epidemiology of Environmental Exposure and Malignant Mesothelioma
High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer  Yu Wu, Jamie R. Schoenborn, Colm Morrissey, Jing Xia, Sandy Larson, Lisha.
Kendy K. Wong, Ronald J. deLeeuw, Nirpjit S. Dosanjh, Lindsey R
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Microarray-Based Comparative Genomic Hybridization Using Sex-Matched Reference DNA Provides Greater Sensitivity for Detection of Sex Chromosome Imbalances.
Volume 131, Issue 6, Pages (December 2006)
Amplification of Whole Tumor Genomes and Gene-by-Gene Mapping of Genomic Aberrations from Limited Sources of Fresh-Frozen and Paraffin-Embedded DNA  Markus.
Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.
Epidemiology of Environmental Exposure and Malignant Mesothelioma
Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 
Assessment of Differentiation and Progression of Hepatic Tumors Using Array-Based Comparative Genomic Hybridization  Doris Steinemann, Britta Skawran,
Array-CGH Reveals Recurrent Genomic Changes in Merkel Cell Carcinoma Including Amplification of L-Myc  Kelly G. Paulson, Bianca D. Lemos, Bin Feng, Natalia.
Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K
Volume 133, Issue 5, Pages (November 2007)
Alterations of the Cell-Cycle Inhibitors p27KIP1 and p16INK4a Are Frequent in Blastic Plasmacytoid Dendritic Cell Neoplasms  Thomas Wiesner, Anna C. Obenauf,
Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer  Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.
Comparative Genomic Hybridization Analysis of Astrocytomas
MET Mutation Associated with Responsiveness to Crizotinib
Whole-Genome Scanning by Array Comparative Genomic Hybridization as a Clinical Tool for Risk Assessment in Chronic Lymphocytic Leukemia  Shelly R. Gunn,
A Tumor Sorting Protocol that Enables Enrichment of Pancreatic Adenocarcinoma Cells and Facilitation of Genetic Analyses  Zachary S. Boyd, Rajiv Raja,
An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,
Victoria Wang, MD, PhD, Trever Bivona, MD, PhD 
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer  Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,
Microarray Techniques to Analyze Copy-Number Alterations in Genomic DNA: Array Comparative Genomic Hybridization and Single-Nucleotide Polymorphism Array 
A comparative genomic hybridization study in a 46,XX male
Multiplex Ligation-Dependent Probe Amplification Versus Multiprobe Fluorescence in Situ Hybridization To Detect Genomic Aberrations in Chronic Lymphocytic.
Volume 69, Issue 5, Pages (May 2016)
Cyclin E1 Is Amplified and Overexpressed in Osteosarcoma
Marleen J. ter Avest, BSc, Romane M. Schook, MD, Pieter E
Kelsie L. Thu, BSc, Raj Chari, PhD, William W
Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad  Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.
Multiple Pulmonary Chondroid Hamartoma
Vertebral Collapse Caused by Bone Metastasis
Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design  Arnaud Uguen, MD, Pascale Marcorelles,
Kiran Devisetty, MD, Joseph K. Salama, MD  Journal of Thoracic Oncology 
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping  Sai-Hong Ignatius Ou, MD, PhD,
High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis  Robert A.A. van Boerdonk, MSc, Johannes.
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Accurate single cell 24 chromosome aneuploidy screening using whole genome amplification and single nucleotide polymorphism microarrays  Nathan R. Treff,
Bassem A. Bejjani, Lisa G. Shaffer 
Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib  Oana Pop, MD, Augustin Pirvu,
Histology and genomic copy number alterations in TRAMP tumors.
Defining Ploidy-Specific Thresholds in Array Comparative Genomic Hybridization to Improve the Sensitivity of Detection of Single Copy Alterations in Cell.
Role of Chromosome 3q Amplification in Lung Cancer
“The Best-Laid Plans … Often go Awry …”
High-Resolution Molecular Characterization of 15q11-q13 Rearrangements by Array Comparative Genomic Hybridization (Array CGH) with Detection of Gene Dosage 
A DNA Replication Mechanism for Generating Nonrecurrent Rearrangements Associated with Genomic Disorders  Jennifer A. Lee, Claudia M.B. Carvalho, James.
A Different Method in Diagnosis of Multiple Primary Lung Cancer
Mechanisms of Acquired Resistance to AZD9291
Nivolumab-Induced Acute Diabetes Mellitus and Hypophysitis in a Patient with Advanced Pulmonary Pleomorphic Carcinoma with a Prolonged Tumor Response 
Gayatry Mohapatra, Rebecca A. Betensky, Ezra R
Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report 
Thymoma and Thymic Carcinoma: Molecular Pathology and Targeted Therapy
Antiangiogenesis Induced Tumor Cavitation in Lung Cancer
Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas  Jun Fan, MD  Journal of Thoracic.
Genetic Changes in Squamous Cell Lung Cancer: A Review
Andreas Rimner, MD, Kenneth E. Rosenzweig, MD 
Frequency plots of copy number aberrations (CNAs) are shown for (A) baseline endobronchial lesions of cases (n=12) and (B) baseline endobronchial lesions.
Volume 2, Issue 2, Pages (August 2002)
ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer  Benjamin Solomon, MBBS, PhD, Marileila.
Presentation transcript:

Genetic Heterogeneity in Patients with Multiple Neoplastic Lung Lesions: A Report of Three Cases  Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F. Smit, MD, PhD, Katrien Grünberg, MD, PhD, Gerrit A. Meijer, MD, PhD, José A. Rodriguez, PhD, Bauke Ylstra, PhD, Giuseppe Giaccone, MD, PhD  Journal of Thoracic Oncology  Volume 2, Issue 1, Pages 12-21 (January 2007) DOI: 10.1016/S1556-0864(15)30012-5 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Localization and molecular analysis of tumors from patient 1. (A) A schematic illustration of localization and time of diagnosis of multiple malignant lung lesions in patient 1. (B) Computed tomographic scans of the thorax show lesion 1 in the right lung before and after chemoradiation, and lesion 2 and 3 in the left lung. (C) Genome wide profiles of tumor sites 2 and 3. Tumor DNA of patient 1 was hybridized with normal female reference DNA on a 30K human oligonucleotide array. On the X axis, array elements are ordered according to their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. On the Y axis, ratios are plotted as log2 ratio of the fluorescent intensities of tumor (Cy3) divided by reference (Cy5) signal for each element on the array. Smoothed values are indicated in red. A smoothed log2 ratio close to zero indicates no difference in fluorescence intensity between tumor and reference DNA and, hence, no chromosomal copy number aberrations. Log2 ratios greater or lower than zero indicate gains or losses of chromosomal elements, respectively. For patient 1, similar patterns of chromosomal aberrations can be observed for tumor sites 2 and 3, indicating that these lesions share the same clonal origin. Journal of Thoracic Oncology 2007 2, 12-21DOI: (10.1016/S1556-0864(15)30012-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Localization and molecular analysis of tumors from patient 1. (A) A schematic illustration of localization and time of diagnosis of multiple malignant lung lesions in patient 1. (B) Computed tomographic scans of the thorax show lesion 1 in the right lung before and after chemoradiation, and lesion 2 and 3 in the left lung. (C) Genome wide profiles of tumor sites 2 and 3. Tumor DNA of patient 1 was hybridized with normal female reference DNA on a 30K human oligonucleotide array. On the X axis, array elements are ordered according to their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. On the Y axis, ratios are plotted as log2 ratio of the fluorescent intensities of tumor (Cy3) divided by reference (Cy5) signal for each element on the array. Smoothed values are indicated in red. A smoothed log2 ratio close to zero indicates no difference in fluorescence intensity between tumor and reference DNA and, hence, no chromosomal copy number aberrations. Log2 ratios greater or lower than zero indicate gains or losses of chromosomal elements, respectively. For patient 1, similar patterns of chromosomal aberrations can be observed for tumor sites 2 and 3, indicating that these lesions share the same clonal origin. Journal of Thoracic Oncology 2007 2, 12-21DOI: (10.1016/S1556-0864(15)30012-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Localization and molecular analysis of tumors from patient 2. (A) Schematic illustration of localization and time of diagnosis of the various malignant lung lesions of patient 2. (B) Computed tomographic scans of the thorax. Lesion 2 can be observed in the right lung and lesion 3 in the left lung. (C) Chromosomal aberration plots are depicted of lesion 2 and 3. Tumor DNA of patient 2 was hybridized with normal male DNA on a 6K human BAC array. Log2 ratios are displayed against their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. Smoothed values are indicated in red. The chromosomal aberration patterns differ between tumor site 2 and 3. In particular, site 3 shows a log2 ratio of –0.35 at chromosome 3, 6, 9, 10, and 14q (arrows), these areas have a lower intensity of fluorescence in tumor DNA versus reference DNA, indicating that these chromosomal regions are deleted. The smoothed log2 ratio of +1.4 on chromosome 14p (arrow) indicates that this chromosomal area has a high copy number in comparison to the reference DNA. These narrow, high-level gains are referred to as amplification.21 Thus, in patient 2, less chromosomal aberrations are present in site 2 versus site 3, indicating they arose from different clones. Journal of Thoracic Oncology 2007 2, 12-21DOI: (10.1016/S1556-0864(15)30012-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Localization and molecular analysis of tumors from patient 2. (A) Schematic illustration of localization and time of diagnosis of the various malignant lung lesions of patient 2. (B) Computed tomographic scans of the thorax. Lesion 2 can be observed in the right lung and lesion 3 in the left lung. (C) Chromosomal aberration plots are depicted of lesion 2 and 3. Tumor DNA of patient 2 was hybridized with normal male DNA on a 6K human BAC array. Log2 ratios are displayed against their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. Smoothed values are indicated in red. The chromosomal aberration patterns differ between tumor site 2 and 3. In particular, site 3 shows a log2 ratio of –0.35 at chromosome 3, 6, 9, 10, and 14q (arrows), these areas have a lower intensity of fluorescence in tumor DNA versus reference DNA, indicating that these chromosomal regions are deleted. The smoothed log2 ratio of +1.4 on chromosome 14p (arrow) indicates that this chromosomal area has a high copy number in comparison to the reference DNA. These narrow, high-level gains are referred to as amplification.21 Thus, in patient 2, less chromosomal aberrations are present in site 2 versus site 3, indicating they arose from different clones. Journal of Thoracic Oncology 2007 2, 12-21DOI: (10.1016/S1556-0864(15)30012-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Localization and molecular analysis of tumors from patient 3. (A) Localization and time of diagnosis of the various malignant lung lesions of patient 3. (B) Computed tomography scans of the thorax in which lesions 1, 2, 3, and 4 can be observed. (C) Chromosomal aberration patterns of site 1, 2, and 4. Tumor DNA of patient 3 was hybridized with normal male reference DNA on a 30K human oligonucleotide array. Log2 ratios are displayed against their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. Smoothed values are indicated in red. The chromosomal aberrations of tumor 1 and 2 follow a similar pattern, suggesting they share the same clonal origin. The pattern of chromosomal aberrations of tumor site 4 differs at various sites compared with tumor site 1 and 2, most obviously at chromosome 6 and 7 (arrows). (D) In site 1, the log2 ratios of chromosome 6p, 6q, and 7p are +0.08, −0.22, and +0.15, respectively. In site 2, the log2 ratios of chromosome 6p, 6q, and 7p are +0.13, −0.18, and +0.12, respectively. Site 4, however, shows a log2 ratio of −0.01 for chromosome 6p-q, and the log2 ratio for chromosome 7p is zero. Because tumor site 4 has a much less altered chromosomal aberration pattern, it is likely that tumor 4 originated from a different clone than tumors 1 and 2. Journal of Thoracic Oncology 2007 2, 12-21DOI: (10.1016/S1556-0864(15)30012-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Localization and molecular analysis of tumors from patient 3. (A) Localization and time of diagnosis of the various malignant lung lesions of patient 3. (B) Computed tomography scans of the thorax in which lesions 1, 2, 3, and 4 can be observed. (C) Chromosomal aberration patterns of site 1, 2, and 4. Tumor DNA of patient 3 was hybridized with normal male reference DNA on a 30K human oligonucleotide array. Log2 ratios are displayed against their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. Smoothed values are indicated in red. The chromosomal aberrations of tumor 1 and 2 follow a similar pattern, suggesting they share the same clonal origin. The pattern of chromosomal aberrations of tumor site 4 differs at various sites compared with tumor site 1 and 2, most obviously at chromosome 6 and 7 (arrows). (D) In site 1, the log2 ratios of chromosome 6p, 6q, and 7p are +0.08, −0.22, and +0.15, respectively. In site 2, the log2 ratios of chromosome 6p, 6q, and 7p are +0.13, −0.18, and +0.12, respectively. Site 4, however, shows a log2 ratio of −0.01 for chromosome 6p-q, and the log2 ratio for chromosome 7p is zero. Because tumor site 4 has a much less altered chromosomal aberration pattern, it is likely that tumor 4 originated from a different clone than tumors 1 and 2. Journal of Thoracic Oncology 2007 2, 12-21DOI: (10.1016/S1556-0864(15)30012-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Localization and molecular analysis of tumors from patient 3. (A) Localization and time of diagnosis of the various malignant lung lesions of patient 3. (B) Computed tomography scans of the thorax in which lesions 1, 2, 3, and 4 can be observed. (C) Chromosomal aberration patterns of site 1, 2, and 4. Tumor DNA of patient 3 was hybridized with normal male reference DNA on a 30K human oligonucleotide array. Log2 ratios are displayed against their position on the genome. Odd and even chromosomes are indicated in light and dark blue, respectively. Smoothed values are indicated in red. The chromosomal aberrations of tumor 1 and 2 follow a similar pattern, suggesting they share the same clonal origin. The pattern of chromosomal aberrations of tumor site 4 differs at various sites compared with tumor site 1 and 2, most obviously at chromosome 6 and 7 (arrows). (D) In site 1, the log2 ratios of chromosome 6p, 6q, and 7p are +0.08, −0.22, and +0.15, respectively. In site 2, the log2 ratios of chromosome 6p, 6q, and 7p are +0.13, −0.18, and +0.12, respectively. Site 4, however, shows a log2 ratio of −0.01 for chromosome 6p-q, and the log2 ratio for chromosome 7p is zero. Because tumor site 4 has a much less altered chromosomal aberration pattern, it is likely that tumor 4 originated from a different clone than tumors 1 and 2. Journal of Thoracic Oncology 2007 2, 12-21DOI: (10.1016/S1556-0864(15)30012-5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions